Tag Archives: NASDAQ:CPRX

Catalyst Pharma (CPRX) Gets a Buy Rating from Oppenheimer

Oppenheimer analyst Leland Gershell assigned a Buy rating to Catalyst Pharma (CPRX – Research Report) today and set a price target of $8.00. The company’s shares closed last Monday at $4.13. According to TipRanks.com, Gershell is a 5-star analyst with

Oppenheimer Reaffirms Their Buy Rating on Catalyst Pharma (CPRX)

In a report released yesterday, Leland Gershell from Oppenheimer maintained a Buy rating on Catalyst Pharma (CPRX – Research Report), with a price target of $10.00. The company’s shares closed last Wednesday at $4.16. According to TipRanks.com, Gershell is a

Catalyst Pharma (CPRX) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Catalyst Pharma (CPRX – Research Report) today and set a price target of $9.00. The company’s shares closed last Monday at $3.80. According to TipRanks.com, Fein is a 5-star analyst

The CMO of Catalyst Pharma (NASDAQ: CPRX) is Selling Shares

Yesterday, the CMO of Catalyst Pharma (CPRX – Research Report), Gary Ingenito, sold shares of CPRX for $723K. Over the last month, Gary Ingenito has reported another 5 Sell trades on CPRX for a total of $1.49M. See today’s analyst

The CMO of Catalyst Pharma (NASDAQ: CPRX) is Buying Shares

Yesterday, the CMO of Catalyst Pharma (CPRX – Research Report), Gary Ingenito, bought shares of CPRX for $79K. Following this transaction Gary Ingenito’s holding in the company was increased by 100%. See today’s analyst top recommended stocks >> Based on

H.C. Wainwright Keeps a Buy Rating on Catalyst Pharma (CPRX)

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Catalyst Pharma (CPRX – Research Report), with a price target of $9.00. The company’s shares closed last Monday at $4.96. According to TipRanks.com, Fein is